CDC Halts Hazardous Biomaterial Transfers

Following recent high-profile safety lapses in government labs, the US Centers for Disease Control and Prevention has placed a moratorium on movement of biological materials from BSL-3 and BSL-4 facilities.

Written byTracy Vence
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

CDCThe US Centers for Disease Control and Prevention (CDC) is investigating yet another safety incident after the agency’s influenza lab personnel reported the inadvertent contamination of an avian influenza virus sample shipped to a US Department of Agriculture facility (USDA) with the highly pathogenic H5N1. The incident, announced today (July 11), is the third safety breach within the last month, with a CDC lab seeing the release of—and potential exposure of dozens of employees to—anthrax bacteria in mid-June, followed by the discovery of six forgotten vials of smallpox virus in US Food and Drug Administration (FDA) storage this week.

Coinciding with the release of a report reviewing the anthrax incident, the CDC has placed a moratorium on movement of biological materials from biosafety level (BSL)-3 and BSL-4 facilities. Additionally, the agency announced Michael Bell, deputy director of the Division of Healthcare Quality Promotion, as its new director of lab safety, reporting directly to CDC Director Thomas Frieden.

During a press briefing today, Frieden said six weeks passed before the H5N1 contamination incident was reported to agency officials. “That kind of delay is very troubling,” Frieden said, noting that no one was exposed to the flu virus, which has since been destroyed.

Tests on the samples found in FDA storage revealed that two of the six contained viable smallpox virus, Frieden said today.

“These events ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies